Monoclonal antibody-based immunohistochemical demonstration of Entamoeba histolytica in liver tissues of experimentally infected hamster (Mesocricetus auratus).
Histopathological changes and the presence of Entamoeba histolytica trophozoites was sequentially followed after intrahepatic inoculation of the parasites in 42 hamsters, 35 of which received no treatment whereas the remaining seven were treated with metronidazole. The liver tissues were examined for amoebic trophozoites by a monoclonal antibody (mAb)-based immunofluorescence assay (IFA), a mAb-based immunoperoxidase (IPx) and H & E staining. The number of hamsters developing abscesses was increased with time and was highest on day 30. Cellular infiltration with inflammatory cells and glycogen depletion were observed as early as day 5, followed thereafter by more intense inflammation of portal canals, periportal fibrosis, bile duct proliferation and hepatocyte degeneration. In 7 metronidazole-treated hamsters, no obvious pathological damage was seen. In a group of seven hamsters each, both IPx and IFA were positive in 3, 3, 4, 5 and 4 hamsters and in 3, 4, 3, 3 and 5 hamsters on days 5, 10, 15, 20 and 30, respectively. In 18 control hamsters, IPx, IFA and H & E were all negative. If the result from H & E was used as a gold standard, agreement between H & E and IFA and H & E and IPx were 91.4%, and 88.6%, respectively. Sensitivity and specificity were 93.8% and 89.5%, respectively for IFA, and 93.8% and 84.2%, respectively for IPx.
Sherchand
J B
JB
Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Thammapalerd
N
N
Riganti
M
M
Tharavanij
S
S
Punpoowong
B
B
D000818:Animals; D000911:Antibodies, Monoclonal; D006224:Cricetinae; D004748:Entamoeba histolytica / Q000302:isolation & purification*; D004749:Entamoebiasis / Q000188:drug therapy / Q000473:pathology*; D005455:Fluorescent Antibody Technique; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry / Q000379:methods; D007249:Inflammation; D008099:Liver / Q000469:parasitology* / Q000473:pathology; D008109:Liver Diseases, Parasitic / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008647:Mesocricetus; D008795:Metronidazole / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D008795:Metronidazole